Earnings Highlights
EPS Actual
-1.32
EPS Estimate
-1.09
Revenue Actual
Revenue Estimate
***
key insights Users can access daily market updates, including technical analysis, earnings reports, and sector rotation insights across technology, energy, and financial stocks. LENZ Therapeutics reported a Q1 2026 net loss of $1.32 per share, missing the consensus estimate of a $1.09 loss by 21.05%. The company generated no revenue during the quarter, which is consistent with its pre-commercial stage. Despite the wider-than-expected loss, the stock rose 0.4% in the following session, suggesting that investors may have focused on pipeline milestones rather than the earnings miss.